SOCS-2 Inhibitors
SOCS-2 inhibitors constitute a diverse array of chemicals strategically designed to exert inhibitory effects on the suppressor of cytokine signaling 2 (SOCS-2). This intricate class of compounds operates by targeting specific signaling pathways to intricately modulate the expression and activity of SOCS-2, thereby indirectly influencing its pivotal regulatory effects on cytokine signaling. Among the notable inhibitors, Curcumin and Tofacitinib stand out as agents adept at addressing the JAK/STAT pathway. By inhibiting JAK proteins, they disrupt the negative feedback loop orchestrated by SOCS-2, paving the way for sustained cytokine signaling. Ruxolitinib, a potent JAK inhibitor, takes a direct approach to hinder SOCS-2 by suppressing JAK activity. This targeted interference prevents the induction of SOCS-2 and facilitates continued cytokine signaling. Triptolide and Bay 11-7082 strategically target the NF-κB pathway, impeding the induction of SOCS-2 and amplifying cytokine signaling in the cellular milieu. Piperlongumine and Celastrol employ their inhibitory prowess by modulating NF-κB, thereby influencing the expression and activity of SOCS-2.
S3I-201, another notable player, executes its inhibitory function by directly targeting JAK proteins, thereby inhibiting SOCS-2 and promoting unhindered cytokine signaling. Withaferin A and Betulinic Acid, acting through NF-κB modulation, contribute to the diversified repertoire of SOCS-2 inhibitors. SB203580 takes a distinctive route by targeting the p38 MAPK pathway, orchestrating the suppression of SOCS-2 and further emphasizing the multifaceted strategies employed to interfere with SOCS-2 function. Collectively, these inhibitors represent a sophisticated arsenal, each wielding a unique mechanism to counteract the inhibitory influence of SOCS-2 on cytokine signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin inhibits SOCS-2 indirectly by suppressing the JAK/STAT pathway. It interferes with the activation of JAK, preventing its phosphorylation and subsequent recruitment of SOCS-2. The inhibition of JAK/STAT signaling by curcumin leads to decreased expression and activity of SOCS-2, thereby attenuating its regulatory effects on cytokine signaling. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK inhibitor that directly impedes the activity of JAK proteins. By inhibiting JAK, Ruxolitinib disrupts the downstream signaling cascade, ultimately suppressing the induction of SOCS-2. This direct inhibition of JAK prevents the negative feedback loop mediated by SOCS-2, allowing sustained cytokine signaling. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide inhibits SOCS-2 by targeting the NF-κB signaling pathway. It interferes with the activation of NF-κB, preventing its translocation to the nucleus and subsequent induction of SOCS-2 expression. The inhibition of NF-κB by triptolide leads to reduced levels of SOCS-2, thereby enhancing cytokine signaling and mitigating the inhibitory effects imposed by SOCS-2 on the JAK/STAT pathway. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Bay 11-7082 inhibits SOCS-2 by targeting the NF-κB pathway. It prevents the activation of NF-κB, hindering its translocation to the nucleus and subsequent induction of SOCS-2 expression. The inhibition of NF-κB by Bay 11-7082 leads to reduced levels of SOCS-2, thereby enhancing cytokine signaling and mitigating the inhibitory effects imposed by SOCS-2 on the JAK/STAT pathway. | ||||||
Stat3 Inhibitor III, WP1066 | 857064-38-1 | sc-203282 | 10 mg | $132.00 | 72 | |
WP1066 inhibits SOCS-2 indirectly by suppressing the JAK/STAT pathway. It interferes with the activation of JAK, preventing its phosphorylation and subsequent recruitment of SOCS-2. The inhibition of JAK/STAT signaling by WP1066 leads to decreased expression and activity of SOCS-2, thereby attenuating its regulatory effects on cytokine signaling. | ||||||
Piperlongumine | 20069-09-4 | sc-364128 | 10 mg | $107.00 | ||
Piperlongumine inhibits SOCS-2 indirectly by modulating the NF-κB pathway. It interferes with the activation of NF-κB, preventing its translocation to the nucleus and subsequent induction of SOCS-2 expression. The inhibition of NF-κB by Piperlongumine leads to reduced levels of SOCS-2, thereby enhancing cytokine signaling and mitigating the inhibitory effects imposed by SOCS-2 on the JAK/STAT pathway. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $148.00 | 104 | |
S3I-201 inhibits SOCS-2 by directly targeting JAK proteins. It disrupts JAK activity, preventing its phosphorylation and subsequent recruitment of SOCS-2. The direct inhibition of JAK by S3I-201 prevents the negative feedback loop regulated by SOCS-2, allowing sustained cytokine signaling. | ||||||
Celastrol, Celastrus scandens | 34157-83-0 | sc-202534 | 10 mg | $155.00 | 6 | |
Celastrol inhibits SOCS-2 by targeting the NF-κB signaling pathway. It interferes with the activation of NF-κB, preventing its translocation to the nucleus and subsequent induction of SOCS-2 expression. The inhibition of NF-κB by Celastrol leads to reduced levels of SOCS-2, thereby enhancing cytokine signaling and mitigating the inhibitory effects imposed by SOCS-2 on the JAK/STAT pathway. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $115.00 $337.00 | 3 | |
Betulinic Acid inhibits SOCS-2 by modulating the NF-κB signaling pathway. It interferes with the activation of NF-κB, preventing its translocation to the nucleus and subsequent induction of SOCS-2 expression. The inhibition of NF-κB by Betulinic Acid leads to reduced levels of SOCS-2, thereby enhancing cytokine signaling and mitigating the inhibitory effects imposed by SOCS-2 on the JAK/STAT pathway. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A inhibits SOCS-2 indirectly by modulating the NF-κB pathway. It interferes with the activation of NF-κB, preventing its translocation to the nucleus and subsequent induction of SOCS-2 expression. The inhibition of NF-κB by withaferin A leads to reduced levels of SOCS-2, thereby enhancing cytokine signaling and mitigating the inhibitory effects imposed by SOCS-2 on the JAK/STAT pathway. | ||||||